StockUS listing USHMTXFOTCQBHealthcareCapital Destroyer

Hemostemix Inc(HMTXF) Stock Analysis | Healthcare

USD --+0.00%
Reward31Low
Risk59Medium-High
75%Data
USD —+0.00 (+0.00%) Previous close · OTCQB
Market cap 10.80M
Reward Ratingⓘ31 Low reward assessment · 75% data coverage
Bottom 1% of stocksView factors
Risk Ratingⓘ59 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on HMTXF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Hemostemix Inc?

, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada.

AI Brief Pro

The brief on Hemostemix Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Hemostemix Inc?

, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company is listed on the OTCQB in USA, operating in the Healthcare sector, with a market capitalisation of 10.80M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (31)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.589
Insider Activity
12M windowNo data
No insider activity data available for this ticker.